
Heron Therapeutics HRTX
$ 0.33
5.47%
Heron Therapeutics Cost of Revenue | HRTX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Heron Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.3 M | 38.6 M | 65.1 M | 54.9 M | 46 M | 36.2 M | 61.6 M | 27.5 M | 4.59 M | 35 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.1 M | 35 K | 37.6 M |
Quarterly Cost of Revenue Heron Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.86 M | 10.6 M | - | 11.9 M | 9.86 M | 8.46 M | - | 9.46 M | 10.5 M | 8.44 M | - | 18.2 M | 20.2 M | 16.9 M | - | 14.7 M | 16.2 M | 11.4 M | - | 11.4 M | 14.5 M | 9.21 M | 9.39 M | 7.17 M | 9 M | 10.6 M | 15.9 M | 17.2 M | 13.6 M | 15 M | 11.6 M | 7.58 M | 5.23 M | 3.13 M | 1.34 M | 1.05 M | 1.01 M | 1.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.2 M | 1.01 M | 10.4 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Codexis
CDXS
|
9.34 M | $ 1.42 | 0.33 % | $ 124 M | ||
|
Dynavax Technologies Corporation
DVAX
|
49.4 M | - | - | $ 2.02 B | ||
|
I-Mab
IMAB
|
27.2 M | - | - | $ 866 M | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
Qilian International Holding Group Limited
QLI
|
31.6 M | - | -6.08 % | $ 184 M | ||
|
Happiness Biotech Group Limited
HAPP
|
12.2 M | - | 1.35 % | $ 17.8 M | ||
|
CureVac N.V.
CVAC
|
106 M | - | - | $ 867 M | ||
|
Abcam plc
ABCM
|
91.2 M | - | - | $ 4.9 B | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
MorphoSys AG
MOR
|
58.4 M | - | 2.43 % | $ 254 M | ||
|
Ardelyx
ARDX
|
39.5 M | $ 3.71 | 1.06 % | $ 894 M | ||
|
Arcutis Biotherapeutics
ARQT
|
36.7 M | $ 23.66 | 0.04 % | $ 3.01 B | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
3.71 M | - | -1.58 % | $ 28.1 M | ||
|
Celyad Oncology SA
CYAD
|
515 K | - | - | $ 12.5 M | ||
|
Fortress Biotech
FBIO
|
20.9 M | $ 2.71 | 0.04 % | $ 75.6 M | ||
|
Anika Therapeutics
ANIK
|
49 M | $ 21.0 | 2.08 % | $ 301 M | ||
|
Axsome Therapeutics
AXSM
|
47.5 M | $ 208.35 | 0.16 % | $ 10.4 B | ||
|
Aeterna Zentaris
AEZS
|
4.85 M | - | 5.93 % | $ 314 M | ||
|
BioMarin Pharmaceutical
BMRN
|
717 M | $ 66.43 | 0.04 % | $ 12.7 B | ||
|
BeiGene, Ltd.
BGNE
|
286 M | - | 0.49 % | $ 251 B |